MHRA Tells Devicemakers to Balance Risk With Need to Show Efficacy

International Medical Device Regulatory Monitor
Medtech sponsors should balance the need to demonstrate safety and efficacy with the potential risks to patients when determining the size and duration of a clinical trial, a new guidance by the UK’s Medicines and Healthcare products Regulatory Agency says.

To View This Article:


Buy This Article Now

Add this article to your cart for $40.00